Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Germany tries to halt U.S. interest in firm working on coronavirus vaccine

03/15/2020 | 02:15pm EDT
FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen

Berlin is trying to stop Washington from persuading a German company seeking a coronavirus vaccine to move its research to the United States, prompting German politicians to insist no country should have a monopoly on any future vaccine.

German government sources told Reuters on Sunday that the U.S. administration was looking into how it could gain access to a potential vaccine being developed by a German firm, CureVac.

Earlier, the Welt am Sonntag German newspaper reported that U.S. President Donald Trump had offered funds to lure CureVac to the United States, and the German government was making counter-offers to tempt it to stay.

Responding to the report, the U.S. ambassador to Germany, Richard Grenell, wrote on Twitter: "The Welt story was wrong."

A U.S. official said: "This story is wildly overplayed ... We will continue to talk to any company that claims to be able to help. And any solution found would be shared with the world."

A German Health Ministry spokeswoman, confirming a quote in the newspaper, said: "The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe."

"In this regard, the government is in intensive exchange with the company CureVac," she added.

Welt am Sonntag quoted an unidentified German government source as saying Trump was trying to secure the scientists' work exclusively, and would do anything to get a vaccine for the United States, "but only for the United States."

German Interior Minister Horst Seehofer told a news conference that the government's coronavirus crisis committee would discuss the CureVac case on Monday.

CureVac issued a statement on Sunday, in which it said: "The company rejects current rumors of an acquisition".

CureVac's main investor Dietmar Hopp said he was not selling and wanted CureVac to develop a coronavirus vaccine to "help people not just regionally but in solidarity across the world."

"I would be glad if this could be achieved through my long-term investments out of Germany," he added.

A German Economy Ministry spokeswoman said Berlin "has a great interest" in producing vaccines in Germany and Europe.

She cited Germany's foreign trade law, under which Berlin can examine takeover bids from non-EU, so-called third countries "if national or European security interests are at stake".

EXPERIMENTAL VACCINE

Florian von der Muelbe, CureVac's chief production officer and co-founder, told Reuters last week the company had started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials.

The privately-held company based in Tuebingen, Germany hopes to have an experimental vaccine ready by June or July to then seek the go-ahead from regulators for testing on humans.

On its website, CureVac said CEO Daniel Menichella early this month met Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and senior representatives of pharmaceutical and biotech companies to discuss a vaccine.

CureVac in 2015 and 2018 secured financial backing for development projects from its investor the Bill & Melinda Gates Foundation, working on shots to prevent malaria and influenza.

In the field of so-called mRNA therapeutics, CureVac competes with U.S. biotech firm Moderna and German rival BioNTech, which Pfizer has identified as a potential collaboration partner.

Drugs based on mRNA provide a type of genetic blueprint that can be injected into the body to instruct cells to produce the desired therapeutic proteins. That contrasts with the conventional approach of making these proteins in labs and bio-reactors.

In the case of vaccines, the mRNA prompts body cells to produce so-called antigens, the tell-tale molecules on the surface of viruses, that spur the immune system into action.

Companies working on other coronavirus-vaccine approaches include Johnson & Johnson and INOVIO Pharmaceuticals, Inc..

By Paul Carrel and Andreas Rinke


ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
INOVIO PHARMACEUTICALS, INC. -3.36% 7.76 Delayed Quote.-12.32%
MEMBERS CO., LTD. 4.07% 3450 End-of-day quote.48.77%
MODERNA, INC. -5.38% 430.14 Delayed Quote.311.74%
All news about MODERNA, INC.
09/24INSIDER SELL : Moderna
MT
09/24MODERNA : COVID SCIENCE-Vaccinated pregnant women pass protective antibodies to babies
RE
09/24MODERNA : U.S. administers 388.6 mln doses of COVID-19 vaccines - CDC
RE
09/24MODERNA : U.S. CDC Says 182,958,696 Individuals Have Been Fully Vaccinated Against COVID-1..
RE
09/24MODERNA : CDC director says boosters needed to protect workers
RE
09/24Equities Fluctuate Midday as Real Estate, Tech Among Worst Performers
MT
09/24EXPLAINER : Who's eligible for Pfizer booster shots in US?
AQ
09/24WALGREENS BOOTS ALLIANCE : Who can get a COVID-19 vaccine booster in the United States?
RE
09/24MIDDAY REPORT : US Stocks Fluctuate as Real Estate, Tech Among Worst Performers; Digital C..
MT
09/24US AF : Myths and facts about the vax - debunking common COVID-19 vaccine myths
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 333 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,5x
Yield 2021 -
Capitalization 174 B 174 B -
EV / Sales 2021 7,90x
EV / Sales 2022 7,19x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 430,14 $
Average target price 307,77 $
Spread / Average Target -28,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353
PHARMARON BEIJING CO., LTD.79.90%25 236